share_log

Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023

Q3および2023年現在のQualigen Therapeuticsの企業アップデートを提供します。

Benzinga ·  2023/11/14 17:41
  • Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors
  • Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024
  • Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) --Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation,today provides a corporate update for the third quarter ending September 30, 2023 and to date:

Highlights:

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする